Literature DB >> 17374623

Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.

Susan L Davis1, Jose A Vazquez, Peggy S McKinnon.   

Abstract

BACKGROUND: Candidemia is a major cause of morbidity and mortality in hospitalized patients.
OBJECTIVES: To describe the epidemiology of and risk factors for non-albicans candidemia (NAC) in nonneutropenic adults and the impact of NAC on patient outcomes and treatment cost.
METHODS: We conducted a retrospective cohort analysis comparing demographics and risk factors for Candida albicans candidemia (CAC) versus NAC in 144 nonneutropenic patients with candidemia over a 6 year period (1997-2002) at Detroit Receiving Hospital.
RESULTS: Candida species distribution included albicans (50%), parapsilosis (13%), tropicalis (10%), and glabrata (13%). Predominant species varied by patient care unit, with C. glabrata more common in the medical intensive care unit (ICU) and C. parapsilosis in the burn ICU. In multivariate analysis, NAC was associated with the absence of antibiotic use at the onset of candidemia, recent history of solid tumor, and male sex. NAC was not associated with an increase in mortality or length of stay compared with CAC, but was found to have a higher cost of antifungal therapy ($2030 vs $780; p = 0.05).
CONCLUSIONS: The epidemiology of candidemia is complex and varies among the different patient care units. Specifically, patients appear less likely to develop NAC if they are receiving antibiotics at the onset of candidemia. Increased awareness of risk factors for NAC can be used to guide adequate initial antifungal therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374623     DOI: 10.1345/aph.1H516

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Quantification and optimization of Candida albicans DNA in blood samples using Real- Time PCR.

Authors:  Mojtaba Nabili; Mohsen Ashrafi; Ghasem Janbabaie; Mohamad Taghi Hedayati; Kamran Ali-Moghaddam; Tahereh Shokohi
Journal:  Rep Biochem Mol Biol       Date:  2013-10

2.  Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study.

Authors:  Diamantis P Kofteridis; Antonis Valachis; Dimitra Dimopoulou; Angeliki M Andrianaki; Athanasia Christidou; Sofia Maraki; Nikolaos A Spernovasilis; George Samonis
Journal:  Mycopathologia       Date:  2017-05-19       Impact factor: 2.574

3.  Risk factors for fluconazole-resistant candidemia.

Authors:  José Garnacho-Montero; Ana Díaz-Martín; Emilio García-Cabrera; Maite Ruiz Pérez de Pipaón; Clara Hernández-Caballero; Javier Aznar-Martín; José M Cisneros; Carlos Ortiz-Leyba
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

Review 4.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

5.  Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections.

Authors:  Cassandra Moran; Chelsea A Grussemeyer; James R Spalding; Daniel K Benjamin; Shelby D Reed
Journal:  Am J Infect Control       Date:  2010-02       Impact factor: 2.918

6.  Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.

Authors:  Francesco Giuseppe De Rosa; Alessandro Busca; Maria Rita Capparella; Jean Li Yan; Jalal A Aram
Journal:  Clin Drug Investig       Date:  2021-04-23       Impact factor: 2.859

7.  Anidulafungin: an evidence-based review of its use in invasive fungal infections.

Authors:  Susan L Davis; Jose A Vazquez
Journal:  Core Evid       Date:  2008-07-31

8.  Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, India.

Authors:  P Bhattacharjee
Journal:  Curr Med Mycol       Date:  2016-06

9.  Candidaemia in a tertiary hospital in Nigeria.

Authors:  Rita O Oladele; Rashidi A Bakare; Michael A Petrou; Oyinlola O Oduyebo; Malcolm Richardson
Journal:  Afr J Lab Med       Date:  2014-08-06

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.